One of the significant hurdles in the new FDA therapies for Alzheimer’s Disease (AD) is identifying those patients in the early stages of the disease when alterations in the brain have begun, but early dementia may be problematic to diagnose
FDA therapies for Alzheimer’s
ACSH relies on donors like you. If you enjoy our work, please contribute.
Make your tax-deductible gift today!
Popular articles
ACSH Podcasts
